<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34450619</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1460-2091</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>76</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of antimicrobial chemotherapy</Title>
          <ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.</ArticleTitle>
        <Pagination>
          <StartPage>3286</StartPage>
          <EndPage>3295</EndPage>
          <MedlinePgn>3286-3295</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkab318</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection.</AbstractText>
          <AbstractText Label="METHODS">We undertook a dose-escalating, open-label, randomized-controlled (standard-of-care) Bayesian adaptive Phase I trial at the Royal Liverpool and Broadgreen Clinical Research Facility. Participants (adult outpatients with PCR-confirmed SARS-CoV-2 infection within 5 days of symptom onset) were randomized 2:1 in groups of 6 participants to 300, 600 and 800 mg doses of molnupiravir orally, twice daily for 5 days or control. A dose was judged unsafe if the probability of 30% or greater dose-limiting toxicity (the primary outcome) over controls was 25% or greater. Secondary outcomes included safety, clinical progression, pharmacokinetics and virological responses.</AbstractText>
          <AbstractText Label="RESULTS">Of 103 participants screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated at 300, 600 and 800 mg doses with no serious or severe adverse events. Overall, 4 of 4 (100%), 4 of 4 (100%) and 1 of 4 (25%) of the participants receiving 300, 600 and 800 mg molnupiravir, respectively, and 5 of 6 (83%) controls, had at least one adverse event, all of which were mild (≤grade 2). The probability of ≥30% excess toxicity over controls at 800 mg was estimated at 0.9%.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Molnupiravir was safe and well tolerated; a dose of 800 mg twice daily for 5 days was recommended for Phase II evaluation.</AbstractText>
          <CopyrightInformation>© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Khoo</LastName>
            <ForeName>Saye H</ForeName>
            <Initials>SH</Initials>
            <Identifier Source="ORCID">0000-0002-2769-0967</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fitzgerald</LastName>
            <ForeName>Richard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fletcher</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ewings</LastName>
            <ForeName>Sean</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jaki</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>University of Lancaster, Bailrigg, Lancaster, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lyon</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Downs</LastName>
            <ForeName>Nichola</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walker</LastName>
            <ForeName>Lauren</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tansley-Hancock</LastName>
            <ForeName>Olana</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greenhalf</LastName>
            <ForeName>William</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woods</LastName>
            <ForeName>Christie</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reynolds</LastName>
            <ForeName>Helen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marwood</LastName>
            <ForeName>Ellice</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mozgunov</LastName>
            <ForeName>Pavel</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>University of Lancaster, Bailrigg, Lancaster, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adams</LastName>
            <ForeName>Emily</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bullock</LastName>
            <ForeName>Katie</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holman</LastName>
            <ForeName>Wayne</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics, 3480 Main Highway, Miami, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bula</LastName>
            <ForeName>Marcin D</ForeName>
            <Initials>MD</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gibney</LastName>
            <ForeName>Jennifer L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saunders</LastName>
            <ForeName>Geoffrey</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corkhill</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hale</LastName>
            <ForeName>Colin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool University Hospital NHS Foundation Trust, Prescot Road, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thorne</LastName>
            <ForeName>Kerensa</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chiong</LastName>
            <ForeName>Justin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Condie</LastName>
            <ForeName>Susannah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pertinez</LastName>
            <ForeName>Henry</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Painter</LastName>
            <ForeName>Wendy</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Ridgeback Biotherapeutics, 3480 Main Highway, Miami, FL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wrixon</LastName>
            <ForeName>Emma</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Lucy</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeats</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mallard</LastName>
            <ForeName>Kim</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Radford</LastName>
            <ForeName>Mike</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fines</LastName>
            <ForeName>Keira</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shaw</LastName>
            <ForeName>Victoria</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Owen</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University of Liverpool, 70 Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lalloo</LastName>
            <ForeName>David G</ForeName>
            <Initials>DG</Initials>
            <AffiliationInfo>
              <Affiliation>Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacobs</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Royal Free London NHS Foundation Trust, Pond Street, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Griffiths</LastName>
            <ForeName>Gareth</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Southampton Clinical Trials Unit, University of Southampton, Tremona Road, Southampton, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>MC_UU_00002/14</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>221590/Z/20/Z</GrantID>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MR/V028391/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>221590</GrantID>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Antimicrob Chemother</MedlineTA>
        <NlmUniqueID>7513617</NlmUniqueID>
        <ISSNLinking>0305-7453</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>20</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34450619</ArticleId>
        <ArticleId IdType="mid">EMS134033</ArticleId>
        <ArticleId IdType="pmc">PMC8598307</ArticleId>
        <ArticleId IdType="doi">10.1093/jac/dkab318</ArticleId>
        <ArticleId IdType="pii">6358705</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Cevik M, Tate M, Lloyd O. 
et al.
SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021; 2: e13–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7837230</ArticleId>
            <ArticleId IdType="pubmed">33521734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Griffiths G, Fitzgerald R, Jaki T. 
et al.
AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials 2020; 21: 544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7303573</ArticleId>
            <ArticleId IdType="pubmed">32560744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wahl A, Gralinski L, Johnson C. 
et al.
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021; 591: 451–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenke K, Hansen F, Schwarz B. 
et al.
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun 2021; 12: 2295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cox RM, Wolf JD, Plemper RK.. 
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol 2021; 6: 11–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Painter WP, Holman W, Bush JA. 
et al.
Human safety, tolerability, and pharmacokinetics of a novel broad-spectrum oral antiviral compound, molnupiravir, with activity against SARS-CoV-2. Antimicrob Agents Chemother 2021; 65: e02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Painter WP, Sheahan T, Baric R. 
et al. Reduction in infectious SARS-CoV-2 in treatment study of COVID-19 with molnupiravir. Virtual Conference on Retroviruses and Opportunistic Infections, 2021. Abstract 777.</Citation>
        </Reference>
        <Reference>
          <Citation>
Mozgunov P, Jaki T, Paoletti X.. 
Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. J Biopharm Stat 2019; 29: 359–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30352007</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
